Ordering
Available Variants10 mg
CHA.85405-10mg
Price
€108.12
Available – Dispatch in 14 days
50 mg
CHA.85405-50mg
Price
€504.00
Available – Dispatch in 14 days
100 mg
CHA.85405-100mg
Price
€74.40
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.85405-10mg | €108.12 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.85405-50mg | €504.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
100 mg | CHA.85405-100mg | €74.40 |
≥98% (HPLC), HERG channel blocker, solid
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C26H30Cl2F3NO · HCl |
|---|---|
| CAS Number | 36167-63-2 |
| Molecular Weight | 536.88 |
| NACRES | NA.77 |
| PubChem Substance ID | 329815264 |
| UNSPSC Code | 12352200 |
| EC Number | 252-895-4 |
| MDL number | MFCD00879136 |
| Assay | ≥98% (HPLC) |
| Form | solid |
| Quality level | 100 |
| Storage condition | desiccated |
Safety Information Handling visibility
| hcodes | H413 |
|---|---|
| pcodes | P273 - P501 |
| Hazard Classifications | Aquatic Chronic 4 |
| Storage Class | 11 - Combustible Solids |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
| ppe | Eyeshields, Gloves, type N95 (US) |
Technical Overview & Applications Use-case context
Halofantrine hydrochloride, with a CAS number of 3336-40-1, is a synthetic antimalarial agent that has been utilized in the treatment of malaria. It functions by interfering with the growth and replication of the Plasmodium parasite, which is the causative agent of the disease. Halofantrine hydrochloride is typically administered orally and has been shown to be effective against certain strains of the parasite, including those resistant to other antimalarial drugs. However, its use has been associated with potential side effects, including cardiac issues, and therefore requires careful consideration and monitoring. As a result, halofantrine hydrochloride is often reserved for the treatment of uncomplicated malaria in areas where other options are not available or effective, and its use is typically guided by local health authorities and treatment guidelines. Its chemical properties and pharmacokinetics have been well-characterized.
